Last reviewed · How we verify
BCG-Denmark
At a glance
| Generic name | BCG-Denmark |
|---|---|
| Also known as | BCG-AJ, BCG-SSI, BCG-1331 |
| Sponsor | Bandim Health Project |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Diabetes Diagnosis, Management, Prevention and Education in Guinea-Bissau (PHASE4)
- BCG Revaccination With the Third Dose of Diphtheria-tetanus-pertussis Vaccine and Infant Mortality in Africa (PHASE4)
- Melbourne Infant Study - Bacille Calmette Guérin (BCG) for Allergy & Infection Reduction (PHASE3)
- BCG Vaccination to Protect Healthcare Workers Against COVID-19 (PHASE3)
- Using BCG to Protect Senior Citizens During the COVID-19 Pandemic (PHASE3)
- Trial to Compare BCG-Bulgaria and BCG-Denmark (PHASE4)
- BCG to Reduce Absenteeism Among Health Care Workers During the COVID-19 Pandemic (PHASE4)
- Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BCG-Denmark CI brief — competitive landscape report
- BCG-Denmark updates RSS · CI watch RSS
- Bandim Health Project portfolio CI